● American Airlines against deal with Qatar Airways. Just a few weeks after, how US President Donald Trump accused Qatar of terrorist financing, Qatar's flagship airline makes a surprise offer to acquire a large stake in American Airlines, Bloomberg reports. Qatar Airways Ltd. interested in acquiring about 10% American Airlines in the amount $808 million, US company says in a statement.
● Major US banks successfully passed new stress test. Investors await news next week on payments of key industry players to shareholders, reports CNBC. Test results, published Thursday by the Federal Reserve (FED), Show, what 34 systemically important US banks have sufficient capital, to withstand the two scenarios presented by the regulator, one of which is related to the financial crisis, and the other – with a lesser decline.
● The video card market will grow by 20% due to cryptocurrencies. The global video card market will end the current quarter with tangible growth due to the growing interest in cryptocurrencies, reported by Pacific Crest Securities. The mining of bitcoin and other digital currencies using graphics accelerators has caused a sharp increase in demand, что вылилось в дефицит видеокарт в нескольких регионах.
● Tesla is thinking about producing electric vehicles in China for the local market. This would allow it to avoid high import duties.
● Medtronic PLC (NYSE: MDT) stated on friday, which will increase the amount of quarterly dividends by 7% to 46 cents per share from 43 cents per share.
● Cable company Altice USA (NYSE: ATUS) debuted on Thursday in the market as a public company. Its placement was the second largest IPO of the year (after Snap) and the largest in the US telecom sector with 2000 G.
Way down
Earnings / guidance response:
- BBBY -10.5%, AMSWA -7.3%, BBRY -4.2%, SONC -2.4%, FINL -2.4%
Other news
- shock -11.6% (names Antony Mattessich to succeed Dr. Amar Sawhney as CEO on or before September 30 )
- WKHS -8.9% (entered into at the market issuance sales agreement with Cowen to offer common stock having an aggregate offering price of up to $25,000,000)
- BLUE -5.8% (presents interim data from the ongoing Northstar-2 (HGB-207) Phase 3 clinical study of LentiGlobin)
- CLSN -4.2% (following late surge higher after canceling its registered direct offering of common stock announced Monday, June 19)
- THE BRIDGE -2.5% (BBBY sympathy)
- WSM -1% (BBBY sympathy)
Analyst Comments:
- HAIN -3% (downgraded to Neutral from Overweight at JP Morgan)
- LEJU -2% (downgraded to Underweight from Neutral at JP Morgan)
- Ultrasound -1.5% (initiated with a Underperform at Credit Suisse)
- SKT -1.4% (downgraded to Underperform from Neutral at BofA/Merrill)
- MELI -1.2% (downgraded to Neutral from Buy at Citigroup)
- CAT -1.1% (downgraded to Hold from Buy at Deutsche Bank)
Up
Earnings / guidance response:
- SGH +2.1%, SNX +0.5%
Select financial names showing strength following stress tests:
- DFS +2.4%, RF +1.5%, BAC +0.9%, WFC +0.8%, C +0.7%, JPM +0.6%, GS +0.6%, .
Other news
- AVEO +60.3% (Eusa Pharma received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending marketing authorisation of FOTIVDA (tivozanib))
- SNCR +34.6% (Siris Capital Group affirms 12.93% active stake, delivers letter indicating that they believe they could be in a position to acquire the Company in an all-cash acquisition at $18.00/share)
- METHOD +10.3% (FDA has granted Breakthrough Therapy designation to I.V. CR845)
- BDSI +7% (announces that Health Canada has issued a Notice of Compliance approving BELBUCA)
- IDRA +6.9% ( confirmed the FDA granted orphan drug designation for IMO-2125, an agonist of endosomal Toll-like receptor 9 for the treatment of melanoma Stages IIb to IV)
- OUR +3.3% ( to sell several non-core assets for up to $70 million; continues to actively market additional non-core assets)
- ADHD +2.7% (conducting a process to explore and review a range of strategic alternatives)
- CNAT +2% (granted orphan designation by the FDA for its compound for the treatment of primary sclerosing cholangitis)
- THC +1.9% (continued strength)
- HIMX +1.8% (increases annual dividend per ADS to $0.24/ADS from $0.12/ADS)
- RIGL +1.4% (Rigel Pharma will present data from its FIT Phase 3 clinical program evaluating the safety and efficacy of TAVALISSE in patients with chronic or persistent immune thrombocytopenia on June 24 from 12:30 – 12:45pm (CESTF) at the European Hematology Association 22nd Annual Congress)
- EVH +1.4% (prices secondary offering by selling shareholders of 4.5 mln shares of common stock at $25.90 per share)
- PFE +1.3% (receives Complete Response Letter from the FDA regarding the Biologics License Application for its proposed epoetin alfa biosimilar)
Analyst Comments:
- CBAY +4.1% (initiated with a Outperform at Oppenheimer)
- AKS +4.1% (upgraded to Buy from Hold at Deutsche Bank)
- X +2.9% (upgraded to Buy from Hold at Deutsche Bank)
- DBVT +2.7% (initiated with a Buy at Deutsche Bank)
- RH +2.2% (upgraded to Buy from Hold at Deutsche Bank )
- VRTX +1.3% (upgraded to Buy from Hold at Needham)
- GILD +1% (initiated with a Buy at Deutsche Bank)
- BIIB +0.9% (initiated with a Buy at Deutsche Bank)
- OCLR +0.8% (initiated with a Buy at DA Davidson)
- SBUX +0.6% (initiated with a Overweight last night after the close at KeyBanc Capital Mkts)
Stock Scanner :
| 52H | 52L | $winner | UP | $ loser |
| JNJ VRTX CELG UTX ARE DLR BLUE RCL WYN RHT CLVS ABC KITE Q MDT PRXL NVS CNC XLV MDSO XBI LOXO ABBV MOH GOOD CCL DFT LUV ATVI BAX |
TAP TJX SLB TSCO WHAT APC PDCE HES NLSN BBBY HAIN DVN |
TSRO PBYI MDSO PVH ORCL NVS PANW GILD CNC KMX ALXN RH CLVS rdus HATE ACHC HCA VNTV EVHC TXRH ABBV GOOD ARE CM SPLK LLY INCY MOH SON BIB |
CLVS GOOD INCY CELG VRTX RHT WFM BIB ALXN BLUE PBYI ESPR XBI BABA SON BMRN KITE ADBE rdus NVS SHOP GILD NOW ORCL TSRO MDSO LOXO DWT WGO PRXL |
BURL ACN WB SINA JDST WLTW DPS AMP CNK BLUE BMRN RCL WBA PRU PNC XPO ST PEP PTLA PFG DUST CB AON BTI DWT BABA HA WHITE EQR OLLI |
